Compounding Versus Manufacturing in Pharmacy Practice: A Regulatory Challenge

This is the authors' abstract. We don't add key points for this paper.

PHARMACY AND pharmacists have not in- ~ recent history felt such a direct threat to the essence of their professional being. The US Food and Drug Administration (FDA) was making headlines throughout the professional literature, both the professional press and the business publications related to pharmaceuti-cals, with the initiatives related to attempting to regulate the compounding activities of pharma-cists. However, has the FDA mounted a frontal attack on the activity that some would describe as one of the main or principal activity compris-ing the definition of the profession and one of the last bastions of unique professional au-tonomy? Or is the regulatory zeal of that agency